Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
MB02 (Bevacizumab Biosimilar Drug)
EU-approved Avastin®
+2 more
Locations
118
Brazil
MedRadius
Maceió, Alagoas, Brazil
Instituto do Câncer do Ceará - ICC
Fortaleza, Ceará, Brazil
Centro Brasileiro de Radioterapia Oncologia e Mastologia
Goiânia, Goiás, Brazil
Hospital Erasto Gaertner - Paranaense de Combate ao Câncer
Curitiba, Paraná, Brazil
Instituto Nacional de Cancer- INCA
Rio de Janeiro, Rio de Janeiro, Brazil
Centro de Pesquisa e Educação da Serra Gaúcha (CEPESG)
Caxias do Sul, Rio Grande do Sul, Brazil
Start Date
February 6, 2018
Primary Completion Date
July 3, 2019
Completion Date
February 27, 2020
Last Updated
April 26, 2021
NCT06043817
NCT07144280
NCT06758401
NCT07431827
NCT06427941
NCT05910827
Lead Sponsor
mAbxience Research S.L.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions